Radiology, Vol 197, 221-226, Copyright © 1995 by Radiological Society of North America

ARTICLES

Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate

J Pruim, AT Willemsen, WM Molenaar, A van Waarde, AM Paans, MA Heesters, KG Go, GM Visser, EJ Franssen and W Vaalburg
National Research Positron Emission Tomography (PET) Center, Groningen, The Netherlands.

PURPOSE: Positron emission tomography (PET) with the amino acid tracer L-[1-C-11]-tyrosine was evaluated in 27 patients with primary and recurrent brain tumors. MATERIALS AND METHODS: Patients underwent either static (n = 14) or dynamic PET (n = 13), with quantification of protein synthesis rate (PSR) and tumor-to-background ratio. Findings were compared with histologic findings. RESULTS: Primary brain tumor was proved in 22 patients histologically, as well as metastatic cancer of unknown origin, primary non-Hodgkin lymphoma, meningioma, atypical infarction, and vasculitis in one patient each. At PET, 20 of 22 primary tumors, the metastasis, and non-Hodgkin lymphoma were correctly depicted. A false-positive finding was obtained with the infarction, and the meningioma and vasculitis were not depicted. The calculated sensitivity was 92%; specificity, 67%; and accuracy, 89%. There were no statistically significant relationships between histologic findings, PSR, and tumor-to-background ratio. CONCLUSION: L-[1-C-11]-tyrosine is a valid tracer for diagnosis of brain tumors and allowed quantification of PSR.

This article has been cited by other articles:

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				J. R. de Boer, J. Pruim, F. W.J. Albers, F. Burlage, W. Vaalburg, and B. F.A.M. van der Laan Prediction of Survival and Therapy Outcome with 11C-Tyrosine PET in Patients with Laryngeal Carcinoma J. Nucl. Med., December 1, 2004; 45(12): 2052 - 2057. [Abstract] [Full Text] [PDF]

				R. Hustinx, C. Lemaire, G. Jerusalem, P. Moreau, D. Cataldo, B. Duysinx, J. Aerts, M.-F. Fassotte, J. Foidart, and A. Luxen Whole-Body Tumor Imaging Using PET and 2-18F-Fluoro-L-Tyrosine: Preliminary Evaluation and Comparison with 18F-FDG J. Nucl. Med., April 1, 2003; 44(4): 533 - 539. [Abstract] [Full Text] [PDF]

				R. M. Pieterman, T. H. Que, P. H. Elsinga, J. Pruim, J. W.G. van Putten, A. T.M. Willemsen, W. Vaalburg, and H. J.M. Groen Comparison of 11C-Choline and 18F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer J. Nucl. Med., February 1, 2002; 43(2): 167 - 172. [Abstract] [Full Text] [PDF]

				P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]

				D. D. Langleben and G. M. Segall PET in Differentiation of Recurrent Brain Tumor from Radiation Injury J. Nucl. Med., November 1, 2000; 41(11): 1861 - 1867. [Abstract] [Full Text] [PDF]

				L. G. Strauss Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology Oncologist, December 1, 1997; 2(6): 381 - 388. [Abstract] [Full Text] [PDF]